2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
- Author:
Jeonghoon HA
1
;
Jung Hwan PARK
;
Kyoung Jin KIM
;
Jung Hee KIM
;
Kyong Yeun JUNG
;
Jeongmin LEE
;
Jong Han CHOI
;
Seung Hun LEE
;
Namki HONG
;
Jung Soo LIM
;
Byung Kwan PARK
;
Jung-Han KIM
;
Kyeong Cheon JUNG
;
Jooyoung CHO
;
Mi-kyung KIM
;
Choon Hee CHUNG
;
Author Information
- Publication Type:Special Article
- From:Endocrinology and Metabolism 2023;38(6):597-618
- CountryRepublic of Korea
- Language:English
- Abstract: Primary aldosteronism (PA) is a common, yet underdiagnosed cause of secondary hypertension. It is characterized by an overproduction of aldosterone, leading to hypertension and/or hypokalemia. Despite affecting between 5.9% and 34% of patients with hypertension, PA is frequently missed due to a lack of clinical awareness and systematic screening, which can result in significant cardiovascular complications. To address this, medical societies have developed clinical practice guidelines to improve the management of hypertension and PA. The Korean Endocrine Society, drawing on a wealth of research, has formulated new guidelines for PA. A task force has been established to prepare PA guidelines, which encompass epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and follow-up care. The Korean clinical guidelines for PA aim to deliver an evidence-based protocol for PA diagnosis, treatment, and patient monitoring. These guidelines are anticipated to ease the burden of this potentially curable condition.
